Publication for CRP and CFHR5

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	CRP	C-reactive protein	1401			[link]
hsa	CFHR5	complement factor H related 5	81494

Pubmed ID	Priority	Text
25855355	0.98	CFHR5 was also shown to bind to C-reactive protein (CRP), an acute phase protein belonging to the family of pentraxins.
	0.97	CRP and incubated with 50 mug/ml FH with or without 20 mug/ml CFHR5, as indicated below the blot, and then C3b and FI were added to each well.
	0.97	CFHR5 and CRP can further fine-tune these interactions, but this needs to be characterized in more detail.
	0.96	CRP for the cleavage of C3b in the presence and absence of CFHR5 was measured by Western blot.
	0.93	CFHR5 when added to heat-inactivated serum significantly reduced the amount of bound FH on PTX3, CRP, and MaxGel (Fig. 8A).
	0.93	CFHR5 may promote complement activation and complement-mediated damage/inflammation through three mechanisms: 1) by preventing the binding of the complement inhibitor FH to PTX3, CRP, and ECM; 2) by allowing increased binding of the complement activation initiator molecule C1q; and 3) by supporting the assembly of the alternative pathway C3 convertase C3bBb.
	0.92	CRP can interact with several members of the FH protein family, namely FH, FHL-1, CFHR4, and CFHR5, but the interaction of FH with the denatured monomeric CRP versus native pentameric CRP is still a controversial issue.
	0.92	CRP (lanes 4-6) were incubated with 50% normal human serum (NHS) (lanes 2 and 5) and a patient serum containing both wild-type CFHR5 and the mutCFHR5 (lanes 3 and 6).
	0.91	CFHR5 and FH occurs also in serum, wells were coated with PTX3, CRP, and MaxGel and incubated with heat-inactivated serum, which was used to exclude FH binding through deposited C3 fragments.
	0.90	CFHR5 dose-dependently inhibited FH binding to PTX3 and also to the monomeric, denatured form of the short pentraxin C-reactive protein.
	0.90	CFHR5 was shown to interact with CRP, but the CRP form that binds to CFHR5 and the functional consequence of this interaction were not investigated.
	0.90	CRP was localized to CCPs 3-7 of CFHR5.
	0.90	CFHR5 with CRP was first described by McRae et al. but the type of CRP that binds CFHR5 was not studied.
	0.89	CRP) and 25% normal human serum (for ECM) were added for 30 min at 37 C, with or without 20 mug/ml CFHR5 or CFHR4A.
	0.78	CRP, and MaxGel was measured in complement active normal serum when CFHR5 was added to increase its concentration.
	0.68	CFHR5 binds to denatured, monomeric CRP and inhibits FH binding and cofactor activity
	0.54	CFHR5 competes with FH in serum for binding to PTX3, CRP, and MaxGel and causes enhanced C3 fragment deposition.
	0.53	CFHR5 and the mutCFHR5 were incubated in wells coated with PTX3 and the related short pentraxin CRP.
19365580	0.97	CFHR5, which shows the highest similarity to CFH, has nine SCRs, with the first two being similar to SCRs 6 and 7 of CFH and therefore having CRP and heparin binding properties.
	0.95	CFHR5 has been proposed to rely upon its recruitment to sites of tissue damage by CRP.
24970127	0.97	CFHR5 were shown to bind to C3b, CFHR1, CFHR3 and CFHR5 to heparin, and CFHR4 and CFHR5 to CRP.
31428091	0.96	FHR-5-CRP interaction, and thereby influence complement activation and control in C3GN.
	0.94	FHR-5 domains 3-7 preferentially interact with the monomeric (mCRP), while FHR-4 domain 1 mainly binds the pentameric form of CRP (pCRP).
	0.92	FHR-5 domain 1 that is homologous to the short consensus repeat 6 of FH, which interacts with CRP.
28572805	0.95	FHR-5 can also compete with FH for binding to CRP, PTX3, and extracellular matrix, resulting in enhancement of complement activation.
22622361	0.94	CFHR5 protein fragment containing SCR1-4, however, did not show CRP and heparin binding, while a SCR3-7 fragment did show binding capacity.